The Life Science industry had a positive year in 2014 with large amounts of new capital being raised to support further research, development and expansion. During the year $883 was raised through venture capital funding, while a further £1,975 was raised on the London Stock Exchange giving a total of $2.86m.
The venture capital funds raised over $500million during 71 rounds, all of which was largely committed to by biotechnology companies. Diagnostic and medical device companies also provided large amounts of capital. With over 56% of the total funds raised coming from companies based within the golden triangle of Oxford, Cambridge and London, this continues to highlight the importance of these areas within the life sciences sectors.
Nearly $2 billion was raised on the London Stock Exchange, with over $1.5 billion, by the biotech, pharma and speciality pharma sectors and $200m by the medical devices industry. The rest was raised by smaller offerings in the diagnostics, CRO and research sectors. One company Circassia Pharmaceuticals raised over $200m alone.
A large amount of finance for Life Science Companies was also raised from funds investing in IP commercialisation.
2015 has also started very positively with organisations raising additional investment, and this additional funding in conjunction with the generous tax climate and the world class academic and research base will strengthen the continued growth in the life sciences industry over the forthcoming years.